Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Inovio Pharmaceuticals, Inc. (INO) had Income from Continuous Operations of $-45.50M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-45.50M |
|
-- |
|
-- |
|
$21.21M |
|
$-21.21M |
|
$-24.29M |
|
$-45.50M |
|
$-45.50M |
|
$-45.50M |
|
|
Income from Continuous Operations |
$-45.50M |
$-45.50M |
|
$-45.50M |
|
$-21.21M |
|
$-20.40M |
|
52.17M |
|
52.17M |
|
$-0.87 |
|
$-0.87 |
|
| Balance Sheet Financials | |
$55.18M |
|
$2.74M |
|
$14.21M |
|
$69.39M |
|
$69.82M |
|
-- |
|
$7.28M |
|
$77.11M |
|
$-7.72M |
|
$-7.72M |
|
$-7.72M |
|
53.57M |
|
| Cash Flow Statement Financials | |
$-69.26M |
|
$14.10M |
|
$25.92M |
|
$65.81M |
|
$36.57M |
|
$-29.25M |
|
$2.99M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.79 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-69.42M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
589.34% |
|
589.34% |
|
-65.57% |
|
589.34% |
|
$-0.14 |
|
$-1.33 |
|
$-1.33 |
|